Soleo Health to offer Xembify

 - 
Thursday, April 2, 2020

FRISCO, Texas – Soleo Health has been selected by Grifols as a limited drug distribution partner for Xembify, which treats primary immunodeficiencies. Soleo was chosen based on its dedicated immunology disorders program and knowledge and experience in the provision of subcutaneous immunoglobulin (IG) services. “Soleo Health’s distinctive model allows us to provide subcutaneous IG delivery across a variety of settings, including the home, ambulatory infusion sites and physicians’ offices,” said Craig Vollmer, chief commercial officer at Soleo.